These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 17385940)

  • 21. Clinical Observation of Botulinum Toxin Injection in the Treatment of Focal Dystonia and Muscle Spasm.
    Zhang Z
    Biomed Res Int; 2022; 2022():1495807. PubMed ID: 36105931
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of botulinum toxin therapy in otorhinolaryngology: experience from 1,000 treatments.
    Helmstaedter V; Wittekindt C; Huttenbrink KB; Guntinas-Lichius O
    Laryngoscope; 2008 May; 118(5):790-6. PubMed ID: 18300708
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Xeomin is free from complexing proteins.
    Frevert J
    Toxicon; 2009 Oct; 54(5):697-701. PubMed ID: 19292989
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Botulinum toxin type B: a new injectable treatment for cervical dystonia.
    Brashear A
    Expert Opin Investig Drugs; 2001 Dec; 10(12):2191-9. PubMed ID: 11772315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new treatment for focal dystonias: incobotulinumtoxinA (Xeomin®), a botulinum neurotoxin type A free from complexing proteins.
    Jimenez-Shahed J
    Neuropsychiatr Dis Treat; 2012; 8():13-25. PubMed ID: 22275842
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Botulinum neurotoxins for the treatment of focal dystonias: Review of rating tools used in clinical trials.
    Del Sorbo F; Albanese A
    Toxicon; 2015 Dec; 107(Pt A):89-97. PubMed ID: 26365917
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Botulinum toxin type A injection for the treatment of frown lines.
    Song KH
    Ann Pharmacother; 1998 Dec; 32(12):1365-7. PubMed ID: 9876820
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An analysis of safety data from five phase III clinical trials on the use of botulinum neurotoxin type A-ABO for the treatment of glabellar lines.
    Rubin M; Dover J; Maas C; Nestor M
    Aesthet Surg J; 2009 Nov; 29(6 Suppl):S50-6. PubMed ID: 19945005
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of a new Botulinum Toxin Type A free of complexing proteins in the treatment of blepharospasm.
    Roggenkämper P; Jost WH; Bihari K; Comes G; Grafe S;
    J Neural Transm (Vienna); 2006 Mar; 113(3):303-12. PubMed ID: 15959841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Review of Tolerance and Safety Profiles of Long-Term Botulinum Neurotoxin Type A in Asian Patients with Hemifacial Spasm and Benign Essential Blepharospasm.
    Lai KKH; Tsang A; Kuk AKT; Ko CKL; Chan E; Ko STC
    Neuroophthalmology; 2021; 45(5):293-300. PubMed ID: 34566211
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment of focal dystonia with botulinum toxin A].
    Sojer M; Wissel J; Müller J; Poewe W
    Wien Klin Wochenschr; 2001; 113 Suppl 4():6-10. PubMed ID: 15506045
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Xeomin: an innovative new botulinum toxin type A.
    Frevert J
    Eur J Neurol; 2009 Dec; 16 Suppl 2():11-3. PubMed ID: 20002741
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines.
    Carruthers A; Carruthers J; Coleman WP; Donofrio L; Flynn T; Gold M; Heinz M; Harrington L; Jones D; McDaniel D; Rohrer T; Schlöbe A; Solish N; Weiss RA
    Dermatol Surg; 2013 Apr; 39(4):551-8. PubMed ID: 23379292
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice.
    Aoki KR
    Toxicon; 2001 Dec; 39(12):1815-20. PubMed ID: 11600142
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Botulinum toxins types A and B for brow furrows: preliminary experiences with type B toxin dosing.
    Lowe NJ; Yamauchi PS; Lask GP; Patnaik R; Moore D
    J Cosmet Laser Ther; 2002 Mar; 4(1):15-8. PubMed ID: 12079632
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Duration of effect of botulinum toxin type A in adult patients with cervical dystonia: a retrospective chart review.
    Brashear A; Watts MW; Marchetti A; Magar R; Lau H; Wang L
    Clin Ther; 2000 Dec; 22(12):1516-24. PubMed ID: 11192142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Botulinum toxins in the treatment of primary focal dystonias.
    Truong D
    J Neurol Sci; 2012 May; 316(1-2):9-14. PubMed ID: 22336699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX) in healthy volunteers.
    Jost WH; Kohl A; Brinkmann S; Comes G
    J Neural Transm (Vienna); 2005 Jul; 112(7):905-13. PubMed ID: 15526142
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Simpson DM; Blitzer A; Brashear A; Comella C; Dubinsky R; Hallett M; Jankovic J; Karp B; Ludlow CL; Miyasaki JM; Naumann M; So Y;
    Neurology; 2008 May; 70(19):1699-706. PubMed ID: 18458230
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity.
    Kaňovský P; Slawek J; Denes Z; Platz T; Comes G; Grafe S; Pulte I
    J Rehabil Med; 2011 May; 43(6):486-92. PubMed ID: 21533328
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.